WEKO3
アイテム
Local Applications of Myostatin-siRNA with Atelocollagen Increase Skeletal Muscle Mass and Recovery of Muscle Function
https://tokushima-u.repo.nii.ac.jp/records/2000182
https://tokushima-u.repo.nii.ac.jp/records/200018267713799-d0de-4080-b45a-e120477c2990
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
pone_8_5_e64719.pdf (805 KB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-10-07 | |||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1371/journal.pone.0064719 | |||||||||||||||||||||||||||||
| 関連名称 | 10.1371/journal.pone.0064719 | |||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||
| タイトル | Local Applications of Myostatin-siRNA with Atelocollagen Increase Skeletal Muscle Mass and Recovery of Muscle Function | |||||||||||||||||||||||||||||
| タイトル別表記 | ||||||||||||||||||||||||||||||
| その他のタイトル | Myostatin-siRNA Therapy for Muscular Dystrophy | |||||||||||||||||||||||||||||
| 著者 |
Kawakami, Emi
× Kawakami, Emi
× 川合, 暢彦× 木内, 奈央× 森, 博世× Ohsawa, Yutaka
× 石丸, 直澄
WEKO
1721
× Sunada, Yoshihide
× 野地, 澄晴
WEKO
120
× 田中, 栄二
WEKO
323
|
|||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||
| 内容記述 | Background: Growing evidence suggests that small-interfering RNA (siRNA) can promote gene silencing in mammalian cells without induction of interferon synthesis or nonspecific gene suppression. Recently, a number of highly specific siRNAs targeted against disease-causing or disease-promoting genes have been developed. In this study, we evaluate the effectiveness of atelocollagen (ATCOL)-mediated application of siRNA targeting myostatin (Mst), a negative regulator of skeletal muscle growth, into skeletal muscles of muscular dystrophy model mice. Methods and Findings: We injected a nanoparticle complex containing myostatin-siRNA and ATCOL (Mst-siRNA/ATCOL) into the masseter muscles of mutant caveolin-3 transgenic (mCAV-3Tg) mice, an animal model for muscular dystrophy. Scrambled (scr) -siRNA/ATCOL complex was injected into the contralateral muscles as a control. Two weeks after injection, the masseter muscles were dissected for histometric analyses. To investigate changes in masseter muscle activity by local administration of Mst-siRNA/ATCOL complex, mouse masseter electromyography (EMG) was measured throughout the experimental period via telemetry. After local application of the Mst-siRNA/ATCOL complex, masseter muscles were enlarged, while no significant change was observed on the contralateral side. Histological analysis showed that myofibrils of masseter muscles treated with the Mst-siRNA/ATCOL complex were significantly larger than those of the control side. Real-time PCR analysis revealed a significant downregulation of Mst expression in the treated masseters of mCAV-3Tg mice. In addition, expression of myogenic transcription factors was upregulated in the Mst-siRNA-treated masseter muscle, while expression of adipogenic transcription factors was significantly downregulated. EMG results indicate that masseter muscle activity in mCAV-3Tg mice was increased by local administration of the Mst-siRNA/ATCOL complex. Conclusion: These data suggest local administration of Mst-siRNA/ATCOL complex could lead to skeletal muscle hypertrophy and recovery of motor disability in mCAV-3Tg mice. Therefore, ATCOL-mediated application of siRNA is a potential tool for therapeutic use in muscular atrophy diseases. |
|||||||||||||||||||||||||||||
| 書誌情報 |
en : PLOS ONE 巻 8, 号 5, p. e64719, 発行日 2013-05-22 |
|||||||||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||||||||
| 収録物識別子 | 19326203 | |||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||
| 出版者 | PLOS | |||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |||||||||||||||||||||||||||||
| EID | ||||||||||||||||||||||||||||||
| 識別子 | 266132 | |||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||
